Cyclica and SK Chemicals Announce Agreement for Joint Development of New Therapies

Cyclic Inc. (“Cyclica”), a neo-biotechnology that is unlocking the protein universe to discover the medicines of tomorrow, and SK Chemicals Co., Ltd. (‘SK Chemicals’), a global leader in total healthcare providing diagnostic, therapeutic and prophylactic solutions, today announced an AI-powered drug discovery and development partnership to develop therapies in a broad range of disease areas.

In collaboration with SK ChemicalsCyclica will deploy its robust proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets in therapeutic areas of mutual interest to Cyclica and SK Chemicals. SK Chemicals he will be responsible for the preclinical and clinical development and worldwide commercialization of these pharmaceutical products.

This partnership is a tremendous opportunity to create innovative drug therapies in a number of therapeutic areas. Having Cyclica e SK Chemicals joining forces will provide both companies with a competitive advantage, enabling major advances in understanding disease mechanisms and the potential development of new therapies for patients,” he said Nahid Kurjico-founder, president and chief executive officer of Cyclica.

We believe Cyclica’s technology will help SK Chemicals develop new therapeutic candidates against difficult biological targets with limited information available. We try to create synergies resulting from the combination SK Chemicals’ organizational excellence and development expertise with Cyclica’s experience and know-how,” he said Yun Ho KimHead of Pharma Business Division at SK Chemicals.

We are thrilled to partner with SK Chemicals. This partnership will leverage our respective strengths in creating new therapies for patients and advancing human health,” added Dr. Vern DeBiasiPhD, Chief Partnership Officer at Cyclica.

About Cyclical

As a neo-biotechnology, Cyclica is efficiently advancing an industry-leading, robust and sustainable drug discovery portfolio focused on CNS, oncology, and autoimmune diseases. Cyclica built the only platform generalizable to the entire proteome, expanding the target space for data-poor targets including AlphaFold2 structures, PPIs and mutant oncogenic targets. Cyclica has assembled a diverse and experienced team of biologists, chemists, computer scientists and business professionals who are collectively passionate about changing the paradigm of drug discovery. By exploring the unexplored and drugging the undrugged, Cyclica strives to impact patient health like never before.

Of SK Chemicals

SK Chemicals is a leading company in the chemical and life sciences industries. Since the founding of Sunkyung Textiles in 1969, SK Chemicals has grown through continuous change and innovation into a chemical and life sciences enterprise representing South Korea. SK Chemicals’ The life sciences business is dominated by pharmaceuticals and biologics and aims to provide comprehensive healthcare solutions that cover patient care from diagnosis to treatment and prevention. The company has established a competitive product portfolio in the pharmaceutical industry with the back-to-back launches of MVIX, an erectile dysfunction treatment, and MVIX S, a film-type erectile dysfunction treatment. In addition to its first new natural medicine, Joins SK Chemicals boasts a diverse line of medicines including arthritis treatment patch, Trast, and blood circulation improvement agent, Ginexin. Learn more at

Forward-looking information

This press release contains forward-looking statements and forward-looking information including, among other things, plans to advance one or more of Cyclica’s drug discovery programs and SK Chemicals. Such statements and information are based on management’s beliefs and assumptions and on information currently available to management and involve risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied in these forecasts. statements and information. While we believe we have a reasonable basis for each of the forward-looking statements and forward-looking information contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known to us and our projections for the future, about which we cannot be sure. We cannot assure you that the forward-looking statements and forward-looking information contained in this press release will prove to be accurate.

Add a Comment

Your email address will not be published. Required fields are marked *